{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"91.0"}]}],"title":"Participants who preferred SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"9.0"}]}],"title":"Participants who preferred IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"91.0"}]}],"title":"Nurses who preferred SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"9.0"}]}],"title":"Nurses who preferred IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC","groups":[{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with fludarabine/cyclophosphamide (FC) prior to Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1400 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 1: Rituximab SC 1400 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1600 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 1: Rituximab SC 1600 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1870 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG002","title":"Part 1: Rituximab SC 1870 mg"}],"paramType":"NUMBER","populationDescription":"All participants in Part 1 were included in this analysis including 8 participants that did not receive SC rituximab.","reportingStatus":"POSTED","timeFrame":"Days 4 to 5 in Cycle 6","title":"Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration","type":"SECONDARY","unitOfMeasure":"percentage of participants or nurses"}